EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment
GSK plc announced that the European Medicines Agency (EMA) has accepted for review its application to expand the use of Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on maintenance treatment for patients with …